Desloratadine: A new, nonsedating, oral antihistamine

摘要: Desloratadine is a new, selective, H(1)-receptor antagonist that also has anti-inflammatory activity. In vitro studies have shown desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and TNF-alpha-induced chemokine RANTES. induction cell adhesion molecules, plateletactivating factor-induced eosinophil chemotaxis, adhesion, spontaneous phorbol myristate acetate-induced superoxide in vitro. animals had no effect on central nervous, cardiovascular, renal, gastrointestinal systems. rapidly absorbed, dose-proportional pharmacokinetics, half-life 27 hours. The absorption not affected by food, metabolism elimination are significantly subject's age, race, sex. There clinically relevant interactions between erythromycin, ketoconazole, grapefruit juice. significant substrate P-glycoprotein transport system. Once daily administration reduces nasal nonnasal symptoms seasonal allergic rhinitis, congestion. patients with rhinitis concomitant asthma, treatment was associated reductions total asthma symptom score use inhaled beta(2)-agonists. Use chronic idiopathic urticaria pruritus, number hives, size largest hive, interference sleep activities. Clinical experience over 2300 adverse event profile similar to placebo; effects electrocardiographic parameters, does impair wakefulness psychomotor performance, exacerbate impairment alcohol use.